QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:RAPT

RAPT Therapeutics (RAPT) Stock Forecast, Price & News

$21.17
+0.12 (+0.57%)
(As of 06/8/2023 ET)
Compare
Today's Range
$20.76
$21.35
50-Day Range
$16.06
$21.34
52-Week Range
$13.31
$32.45
Volume
183,950 shs
Average Volume
424,796 shs
Market Capitalization
$727.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.22

RAPT Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.7% Upside
$41.22 Price Target
Short Interest
Bearish
8.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
0.23mentions of RAPT Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$94,400 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.18) to ($3.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

482nd out of 986 stocks

Pharmaceutical Preparations Industry

225th out of 473 stocks


RAPT stock logo

About RAPT Therapeutics (NASDAQ:RAPT) Stock

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPT Stock News Headlines

Analyst Ratings for RAPT Therapeutics
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
H.C. Wainwright Keeps Their Buy Rating on RAPT Therapeutics (RAPT)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Analyst Expectations for RAPT Therapeutics's Future
Recap: RAPT Therapeutics Q1 Earnings
RAPT Therapeutics (NASDAQ:RAPT) Shares Gap Up to $16.77
RAPT Therapeutics (NASDAQ:RAPT) Shares Down 5.3%
RAPT Therapeutics: Potential Strong Upside Ahead
See More Headlines

RAPT Price History

RAPT Company Calendar

Last Earnings
3/14/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAPT
Fax
N/A
Employees
81
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$41.22
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+94.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-83,840,000.00
Pretax Margin
-10,456.09%

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
$8.20 per share

Miscellaneous

Free Float
32,456,000
Market Cap
$727.19 million
Optionable
Not Optionable
Beta
0.37

Social Links


Key Executives

  • Brian Russell Wong
    President, Chief Executive Officer & Director
  • Rodney K. B. Young
    Chief Financial Officer & Secretary
  • William HoWilliam Ho
    Chief Medical Officer
  • Dirk G. BrockstedtDirk G. Brockstedt
    Chief Scientific Officer
  • Jim Farmer
    Vice President-Clinical Operations













RAPT Stock - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT shares.
View RAPT analyst ratings
or view top-rated stocks.

What is RAPT Therapeutics' stock price forecast for 2023?

8 brokers have issued 1-year target prices for RAPT Therapeutics' shares. Their RAPT share price forecasts range from $23.00 to $48.00. On average, they anticipate the company's share price to reach $41.22 in the next year. This suggests a possible upside of 94.7% from the stock's current price.
View analysts price targets for RAPT
or view top-rated stocks among Wall Street analysts.

How have RAPT shares performed in 2023?

RAPT Therapeutics' stock was trading at $19.80 at the beginning of 2023. Since then, RAPT stock has increased by 6.9% and is now trading at $21.17.
View the best growth stocks for 2023 here
.

When is RAPT Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RAPT earnings forecast
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) issued its earnings results on Tuesday, March, 14th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.03.

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.00%), Price T Rowe Associates Inc. MD (9.67%), Perceptive Advisors LLC (6.67%), BlackRock Inc. (6.33%), State Street Corp (4.77%) and Great Point Partners LLC (3.95%). Insiders that own company stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends
.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $21.17.

How much money does RAPT Therapeutics make?

RAPT Therapeutics (NASDAQ:RAPT) has a market capitalization of $727.19 million and generates $1.53 million in revenue each year. The company earns $-83,840,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rapt.com. The company can be reached via phone at (650) 489-9000 or via email at investors@rapt.com.

This page (NASDAQ:RAPT) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -